Advanced Filters
noise

Jersey City, New Jersey Clinical Trials

A listing of Jersey City, New Jersey clinical trials actively recruiting patient volunteers.

Found 1,803 clinical trials
U Urvi A Shah, MD, MS

A Dietary Study for People With Multiple Myeloma

The purpose of the study is to find out whether a dietary intervention can affect treatment response and/or quality of life for people with newly diagnosed multiple myeloma receiving standard induction chemotherapy with daratumumab (or isatuximab), lenalidomide, bortezomib, and dexamethasone (DRVd). The researchers will measure quality of life by having …

18 years of age All Phase N/A

A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures

This is a clinical research study for an investigational drug called RAP-219 in patients with Refractory Focal Epilepsy. This study is being conducted to determine RAP-219 Long- term safety and open-label antiseizure activity in patients with Refractory Focal Epilepsy.

18 - 70 years of age All Phase 2
C Chrisanna Dobrowolski, MD

Alnuctamab for Refractory SLE (LATTE Study)

This study will assess the safety and preliminary efficacy of the bi-specific TCE, alnuctamab (known as BMS-986349, CC-93269, EM901), targeting BCMA in patients with moderate to severe SLE, refractory to standard-of-care treatments.

18 - 60 years of age All Phase 1
S Sadia Morium

First-in-human Study of 7MW4911 in GI Cancer

This is the first-in-human study of 7MW4911 in US patients, to investigate its prelimary safety and efficacy in patients with gastrointestinal cancers.

18 years of age All Phase 1/2
K Kathleen Ryan, MD

Multicenter Trial of ECMO in Children With Severe Cardiac Failure Using the Cardiohelp System

There are two primary goals of this multicenter clinical trial that combines an FDA device trial and a phase II drug trial in the same study cohort. These two goals are to: To evaluate the safety and effectiveness of the Cardiohelp Device for VA-ECMO (heart-lung support) for up to 30 …

- 16 years of age All Phase 2
G Giselle Singer

Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome

This is a single-center, open-label, basket phase 2b trial that will enroll Down Syndrome (DS) participants with at least one inflammatory skin condition (Atopic Dermatitis (AD) and/or Alopecia Areata (AA)). Patients will receive Abrocitinib 100 mg daily for 12 weeks. Responders (defined as achieving Eczema Area and Severity Index (EASI) …

12 years of age All Phase 2

A Study to Learn About the Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Late Isolated Microvascular Inflammation

In this study, researchers will learn more about a drug called felzartamab in people who have received a kidney transplant and later developed a condition called microvascular inflammation (MVI). MVI is a type of injury to small blood vessels in the transplanted kidney and may be a sign of rejection …

18 - 74 years of age All Phase 2
L Laura Gemmell, MD

HELIOS: Human Embryo Illumination to Enhance Development

Embryos need a lot of energy to grow, but as women get older, the "power plants" of the cells (called mitochondria) don't work as well. This makes it harder for embryos to develop normally. One possible way to help is with a gentle light treatment called photobiomodulation (PBM). This uses …

18 - 48 years of age Female Phase N/A
E Elena Silverman, MS

Study of Cannabidiol and Neuroimaging on Stress

Dysregulation in stress responsivity is a growing psychiatry-transdiagnostic fundamental phenomenon, with limited therapeutic strategies. With the legalization of medical and recreational cannabis, many people consume cannabidiol (CBD; a nonintoxicating cannabinoid) to alleviate stress response, without the benefit of scientific guidance. To address this gap, the investigators propose a rigorous translational …

18 - 25 years of age All Phase 1/2
H Howard S. Hochster, MD

DPYD Pharmacogenomics and Fluoropyrimidine (FP) Dose-Adjustment

To prospectively evaluate the efficacy and safety of DPYD-guided dosing strategies in a real-world clinical setting, specifically by comparing the incidence of severe (Grade 3 and 4) fluoropyrimidine-related toxicities of heterozygous DPYD variant patients assigned to DPYD-guided reduced dosing versus patients with standard dosing in the control arm.

18 years of age All Phase 4

Simplify language using AI